Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

Learn how the molecule EBC-46 could advance how HIV is treated and how researchers discovered it.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...